T-cell receptor-like antibodies: Novel reagents for clinical cancer immunology and immunotherapy

Expert Review of Anticancer Therapy

Volumn 5, Issue 3, 2005, Pages 523-536

  Noy, Roy ^a   Epel, Malka ^a   Haus Cohen, Maya ^a   Klechevsky, Eynav ^a   Makler, Oryan ^a   Michaeli, Yael ^a   Denkberg, Galit ^a   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antibodies; Antibody engineering; Cancer immunotherapy; Immunotoxins; Major histocompatibility complex peptide complex; Phage display; Recombinant antibodies; T cell receptor

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; CYTOTOXIC AGENT; DIFFERENTIATION ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; GAG PROTEIN; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN T CELL LEUKEMIA VIRUS ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOTOXIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MUCIN 1; PEPTIDE DERIVATIVE; REAGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR; TAX PROTEIN; TELOMERASE; TOXIN; TUMOR ANTIGEN; VIRUS PROTEIN;

ANTIBODY ENGINEERING; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COMPLEX FORMATION; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; DRUG PURIFICATION; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PROCEDURES; INFECTION; MALIGNANT TRANSFORMATION; NONHUMAN; PHAGE DISPLAY; REVIEW; T LYMPHOCYTE; TUMOR CELL; VIRUS INFECTION;

ANTIBODIES; ANTIBODY FORMATION; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; EPITOPES; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; LIGANDS; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 21244469866     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.3.523     Document Type: Review

References (75)

1. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725 (1996).
2. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature 411, 380 (2001).
3. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T-cells. Cancer Immunol. Immunother. 50, 3 (2001).
4. Anichini A, Maccalli C, Mortarini R et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T-cell clones from melanoma patients. J. Exp. Med. 177, 989 (1993).
5. Coulie PG, Brichard V, Van Pel A et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35 (1994).
6. Rivoltini L, Loftus DJ, Squarcina P et al. Recognition of melanoma-derived antigens by CTL: possible mechanisms involve in down-regulating anti-tumor T-cell reactivity. Crit. Rev. Immunol. 18, 55 (1998).
7. Offringa R, van der Burg SH, Ossendorp F, Toes RE, Melief CJ. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. Curr. Opin. Immunol. 12, 576 (2000).
8. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265 (1993).
9. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21, 455 (2000).
10. Esche C, Shurin MR, Lotze MT. The use of dendritic cells for cancer vaccination. Curr. Opin. Mol. Ther. 1, 72 (1999).
11. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids [see comments]. Nature Med. 6, 332 (2000).
12. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94 (1996).
13. Klenerman P, Cerundolo V, Dunbar PR. Tracking T-cells with tetramers: new tales from new tools. Nature Rev. Immunol. 2, 263-272 (2002).
14. Panelli MC, Wang E, Monsurro V et al. Vaccination with T-cell-defined antigens. Expert Opin. Biol. Ther. 4, 697-707 (2004).
15. Finn OJ. Cancer vaccines: between the idea and the reality. Nature Rev. Immunol. 3, 630-641 (2003).
16. Stevenson FK, Rice J, Zhu D. Tumor vaccines. Adv. Immunol. 82, 49-103 (2004).
17. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
18. Rosenberg SA. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350, 1461-1463 (2004).
19. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nature Rev. Cancer 3, 666-675 (2003).
20. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 305, 197-200 (2004).
21. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy-mapping the way. Nature Med. 10, 475-480 (2004).
22. Shevach EM. Fatal attraction: tumors beckon regulatory T-cells. Nature Med. 10, 900-901 (2004).
23. + regulatory T-cells and their ligands: implications for immunotherapy. Immunity 20, 107-118 (2004).
24. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6, 715 (1997).
25. Dadaglio G, Nelson CA, Deck MB, Petzold SJ, Unanue ER. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity 6, 727 (1997).
26. Aharoni R, Teitelbaum D, Arnon R, Puri J. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex. Nature 351, 147 (1991).
27. Krogsgaard M, Wucherpfennig KW, Canella B et al. Visualization of myelin basic protein (MBP) T-cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191, 1395 (2000).
28. Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T-cells. Proc. Natl. Acad. Sci. USA 93, 1820 (1996).
29. Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl Acad. Sci. USA 97, 7969 (2000).
30. Wulfing C, Pluckthun A. Correctly folded T-cell receptor fragments in the periplasm of Escherichia coli. Influence of folding catalysts. J. Mol. Biol. 242, 655-669 (1994).
31. Plaksin D, Polakova K, McPhie P, Margulies DH. A three-domain T-cell receptor is biologically active and specifically stains cell surface MHC/peptide complexes. J. Immunol. 158(5), 2218-2227 (1997).
32. O'Herrin SM, Lebowitz MS, Bieler JG et al. Analysis of the expression of peptide-major histocompatibility complexes using high affinity soluble divalent T-cell receptors. J. Exp. Med. 186(8), 1333-1345 (1997).
33. Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD. Directed evolution of a stable scaffold for T-cell receptor engineering. Nature Biotechnol. 18(7), 754-759 (2000).
34. Holler PD, Holman PO, Shusta EV, O'Herrin S, Wittrup KD, Kranz DM. In vitro evolution of a T-cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA 97(10), 5387-5392 (2000).
35. Day PM, Yewdell JW, Porgador A, Germain RN, Bennink JR. Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc. Natl. Acad. Sci. USA 94, 8064-8069 (1997).
36. Reiter Y, Di Carlo A, Fugger L, Engberg J, Pastan I. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T-cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 94, 4631 (1997).
37. Cohen CJ, Denkberg G, Lev A, Epel M, Reiter Y. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J. Mol. Recognit. 16, 324-332 (2003).
38. Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom H, Reiter Y. Direct visualization of distinct T-cell epitopes derived from a melanoma tumor associated antigen by using human recombinant antibodies with MHC-restricted T-cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 99, 9421-9426 (2002).
39. Lev A, Denkberg G, Cohen CJ et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T-cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 62, 3184-3194 (2002).
40. Cohen CJ, Hoffman N, Farago M, Hoogenboom HR, Eisenbach L, Reiter Y. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin (MUC1) using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T-cells. Cancer Res. 62, 5835-5844 (2002).
41. Cohen CJ, Sarig O, Yamano Y, Tomaru U, Jacobson S, Reiter Y. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted TCR-like human recombinant antibodies. J. Immunol. 170, 4349-4361 (2003).
42. Biddison WE, Turner RV, Lev A, Cohen CJ, Reiter Y. Tax and M1 peptide/HLA-A2-specific Fabs and T-cell receptors recognize non-identical structural features on peptide/HLA-A2 complexes. J. Immunol. 171, 3064-3074 (2003).
43. + T-cells detected by TCR-like antibodies in patients with HTLV-1 associated neurologic disease. J. Exp. Med. 199, 1367-1377 (2004).
44. Zehn D, Cohen CJ, Reiter Y, Walden P. Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells. Euro. J. Immunol. 34, 1551-1560 (2004).
45. Held G, Matsuo M, Epel M et al. Dissecting cytotoxic T-cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur. J. Immunol. 34(10), 2919-2929 (2004).
46. Zhong G, Reis e Sousa C, Germain RN. Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein. Proc. Natl. Acad. Sci. USA 94, 13856-13861 (1997).
47. Polakova K, Plaksin D, Chung DH, Belyakov IM, Berzofsky JA, Margulies DH. Antibodies directed against the MHC-I molecule H-2D(d) complexed with an antigenic peptide: similarities to a T-cell receptor with the same specificity. J. Immunol. 165, 5703-5712 (2000).
48. Wylie DE, Sherman LA, Klinman NR. Participation of the major histocompatibility complex in antibody recognition of viral antigens expressed on infected cells. J. Exp. Med. 155 (2), 403-414 (1982).
49. Froscher BG, Klinman NR. Immunization with SV40-transformed cells yields mainly MHC-restricted monoclonal antibodies. J. Exp. Med. 164(1), 196-210 (1986).
50. Tamminen WL, Wraith D, Barber BH. Searching for MHC-restricted anti-viral antibodies: antibodies recognizing the nucleoprotein of influenza virus dominate the serological response of C57BL/6 mice to syngeneic influenza-infected cells. Eur. J. Immunol. 17(7), 999-1006 (1987).
51. Rubin B, Malissen B, Jorgensen PN, Zeuthen J. Recognition of insulin on MHC-class-II-expressing L929 cells by antibody and T-cells. Res. Immunol. 140(1), 67-74 (1989).
52. Abastado JP, Darche S, Jouin H, Delarbre C, Gachelin G, Kourilsky P. A monoclonal antibody recognizes a subset of the H-2Dd mouse major class I antigens. Res. Immunol. 140(5-6), 581-594 (1989).
53. Catipovic B, Dal Porto J, Mage M, Johansen TE, Schneck JP. Major histocompatibility complex conformational epitopes are peptide specific. J. Exp. Med. 176(6), 1611-1618 (1992).
54. Uchanska-Ziegler B, Nossner E, Schenk A, Ziegler A, Schendel DJ. Soluble T-cell receptor-like properties of an HLA-B35-specific monoclonal antibody (TU165). Eur. J. Immunol. 3, 734-738 (1993).
55. Hogquist KA, Grandea AG III, Bevan MJ. Peptide variants reveal how antibodies recognize major histocompatibility complex class I. Eur. J. Immunol. 23(11), 3028-3036 (1993).
56. Benhar I. Biotechnological applications of phage and cell display. Biotechnol. Adv. 19(1), 1-33 (2001).
57. Denkberg G, Cohen CJ, Segal D, Kirkin A, Reiter Y. Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. Eur. J. Immunol. 30, 3522-3532 (2000).
58. Denkberg G, Cohen CJ, Reiter Y. Critical role for CD8 in binding of MHC-peptide complexes to TCR: CD8 antibodies block specific binding of human tumor-specific MHC/peptide tetramers to T-cell receptor. J. Immunol. 167, 270-276 (2001).
59. de Haard HJ, van Neer N, Reurs A et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274, 18218 (1999).
60. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from β2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice. J. Exp. Med. 185, 2043 (1997).
61. FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I. Recombinant immunotoxins for treating cancer. Int. J. Med. Microbiol. 293(7-8), 577-582 (2004).
62. Lode HN, Reisfeld RA. Targeted cytokines for cancer immunotherapy. Immunol. Res. 21, 279-288 (2000).
63. Withoff S, Helfrich W, de Leij LF, Molema G. Bi-specific antibody therapy for the treatment of cancer. Curr. Opin. Mol. Ther. 3, 53-62 (2001).
64. Denkberg G, Lev A, Eisenbach L, Benhar I, Reiter Y. Selective targeting of melanoma and antigen-presenting cells using a recombinant antibody with T-cell receptor-like specificity directed toward a melanoma differentiation antigen. J. Immunol. 171, 2197-2207 (2003).
65. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nature Biotechnol. 17, 568 (1999).
66. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods. 248, 47-66 (2001).
67. Cloutier SM, Couty S, Terskikh A et al. Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Mol. Immunol. 37, 1067-1077 (2000).
68. Denkberg G, Kalchevsky E, Reiter Y. Specific modification of a tumor-derived peptide at an HLA-A2 anchor residue can influence the conformation of the MHC-peptide surface area: probing with T-cell receptor-like recombinant antibodies. J. Immunol. 169, 4399-4407 (2002).
69. Lehner PJ, Cresswell P. Recent developments in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16(1), 82-89 (2004).
70. Garcia KC, Teyton L, Wilson IA. Structural basis of T-cell recognition. Ann. Rev Immunol. 17, 369-397 (1999).
71. Sharma AK, Kuhns JJ, Yan S et al. Class I major histocompatibility complex anchor substitutions alter the conformation of T-cell receptor contacts. J. Biol. Chem. 276(24), 21443-21449 (2001).
72. Stryhn A, Andersen PS, Pedersen LO et al. Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex. Proc. Natl. Acad. Sci. USA 93, 10338-10342 (1996).
73. Rognan D, Stryhn A, Fugger L et al. Modeling the interactions of a peptide-major histocompatibility class I ligand with its receptors. I. Recognition by two αβT-cell receptors. J. Comput. Aided Mol. Des. 14, 53-69 (2000).
74. Hulsmeyer M, Chames P, Hillig RC et al. An MHCpeptide-restricted antibody and TCR molecules recognize their target by distinct binding modes: crystal structure of HLA-A1: MAGE-A1 in complex with Fab-Hyb3. J. Biol. Chem. 280, 2972-2980 (2005).
75. Chames P, Willemsen RA, Rojas G et al. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 169, 1110-1118 (2002).